Biomarker-directed therapy for pancreatic cancer

Michael J. Pishvaian, Jonathan R. Brody

Research output: Chapter in Book/Report/Conference proceedingChapter


Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, and soon will be the second leading cause of cancer-related death in the United States. Chemotherapy has improved outcomes for patients with PDAC, but the median overall survival remains only about 1 year. However, multiple recent studies evaluating the mutational landscape of PDAC have revealed that up to 25% of patient tumors harbor “actionable” mutations—that is, mutations that predict for a high rate of response with appropriately targeted therapy. Herein, we describe the most actionable molecular abnormalities in PDAC, and evaluate the clinical trial experience with appropriately matched therapies. We consider how subdividing PDAC into multiple small biomarker-based subgroups provides a glimpse into the future infrastructure of how precision medicine might work for the treatment of this deadly disease.

Original languageEnglish (US)
Title of host publicationGenomic and Precision Medicine
Subtitle of host publicationOncology, Third Edition
Number of pages16
ISBN (Electronic)9780128006849
ISBN (Print)9780128006535
StatePublished - Jan 1 2022


  • actionable mutations
  • Pancreatic cancer
  • pancreatic ductal adenocarcinoma
  • precision medicine
  • sequencing
  • targeted therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Biomarker-directed therapy for pancreatic cancer'. Together they form a unique fingerprint.

Cite this